<DOC>
	<DOCNO>NCT01440478</DOCNO>
	<brief_summary>This study design explore effect increase decreased urinary pH single pharmacokinetic ( PK ) dose LY2140023 active metabolite LY404039 . All participant receive three treatment randomize order .</brief_summary>
	<brief_title>The Effects Urinary pH Changes Investigational Compound Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>overtly healthy male female , determine medical history physical examination female subject childbearing potential , test negative pregnancy screen . Male subjects/female subject childbearing potential/female subject sterilize tubal ligation partner require use condom ( male condom female condom ) use conjunction spermicidal gel , foam , cream , film , suppository time screening ( female subject ) dose ( male subject ) 3 month last dose investigational product . Male subject female partner childbearing potential female subject childbearing potential request use additional highly effective form contraception first dose occasion 3 month last dose investigational product . The additional method contraception follow : diaphragm cervical vault cap use conjunction spermicidal gel , foam , cream , film , suppository ; male sterilization , appropriate post vasectomy documentation absence sperm ejaculate , female subject vasectomize male partner sole partner subject ; true abstinence ( must due subject 's lifestyle choice ; placement effective hormonal intrauterine device ( IUD ) ( i.e . Mirena Coil ) ( steel copper IUDs acceptable ) ; establish use oral , injected , implanted hormonal method contraception female subject non childbearing potential i.e . post menopausal permanently sterile follow hysterectomy , bilateral salpingectomy confirm tubal occlusion ( tubal ligation ) . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) follicle stimulate hormone ( FSH ) ≥40 mIU/mL body mass index ( BMI ) 19 32 kg/m^2 , inclusive , time screen clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator venous access sufficient allow blood sample reliable willing make available duration study willing follow study procedure give write informed consent approve Lilly choose ethical review board ( ERB ) willing adhere dietary requirement currently enrol , complete discontinue within last 90 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study know allergy LY2140023 , LY404039 , ammonium chloride , sodium bicarbonate , related compound , component formulation person previously receive investigational product study , withdrawn study study investigate LY2140023 LY404039 abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study abnormality serum chemistry calcium , sodium , magnesium , potassium , , opinion investigator , increase risk associate participate study abnormal supine stand blood pressure pulse rate , determine investigator history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data evidence significant active neuropsychiatric disease ( example , manic depressive illness , schizophrenia , depression ) increase risk seizure base history : one seizure ( except single simple febrile seizure [ lack focality last less 15 minute , associated central nervous system ( CNS ) infection severe metabolic disturbance ] child age 6 month 5 year ) head trauma loss consciousness post concussive syndrome within 1 year lifetime history head trauma persistent neurological deficit ( focal diffuse ) CNS infection , uncontrolled migraine transient ischemic attack ( TIA ) within 1 year ; stroke persistent neurological deficit ( focal diffuse ) , uncontrolled migraine define migraine attack produce headache last 72 hour often accompany associate symptom ( nausea , photophobia , phonophobia ) impair wellbeing disrupt social functioning . TIA define `` ministroke '' cause temporary disturbance blood supply area brain , result sudden , brief decrease brain function CNS infection persistent neurological deficit ( focal diffuse ) brain surgery electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity ( isolated spike wave , repetitive burst sharp wave , paroxysmal activity , frank seizure , spikewave complex , sharpslow wave complex , locally define ) brain structural lesion , include developmental abnormality , determine examination image study ( include hydrocephalus unless treat shunt result neurological deficit ) show evidence know substance dependence abuse within 6 month prior study ( accord Diagnostic Statistical Manual Mental Disorders [ DSM IV ] diagnosis ) , regularly use know drug abuse and/or show positive finding urinary drug screen show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate intend use counter ( exclude vitamin/mineral supplement include herbal remedies/health supplement prescription medication ( exclude paracetamol , oral contraceptive hormone replacement therapy ) within 14 day prior dose LY2140023 . If situation arises , inclusion otherwise suitable subject may discretion investigator consultation Lilly Clinical Pharmacologist ( CP ) designee donate blood 500 mL within 3 month prior screen average weekly alcohol intake exceed 28 unit per week ( male age 65 ) 21 unit per week ( female ) , unwilling stop alcohol consumption duration study ( 1 unit equal 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) clinical significant abnormality neurological examination subject judge prior randomization suicidal risk investigator subject unwilling refrain tobacco nicotine containing product Clinical Research Unit ( CRU ) unable abide CRU restriction history , opinion investigator , excessive methylxanthine use within previous 6 month , &gt; 6 cup coffee ( equivalent ) per day show evidence active renal disease ( example , diabetic renal disease , polycystic kidney disease ) creatinine clearance ( CrCL ) less 80 mL/min ( calculate Cockcroft Gault equation ) Men : [ ( 140 age ) * ( weight kg ) * 1.23 ] / ( serum creatinine µmol/L ) . Women : [ ( 140 age ) * ( weight kg ) * 1.04 ] / ( serum creatinine µmol/L ) show evidence pruritus skin exfoliation eosinophil count &gt; 1.5 x 109/L creatine kinase ( CK ) &gt; 5 x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>